A study on the level of oxidative stress and inflammatory markers in type 2 diabetes mellitus patients with different treatment modalities

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 9, 2015, Pages 4-7

  Palem, Siva Prasad ^a   Abraham, Philips ^a  

^a VINAYAKA MISSION S RESEARCH FOUNDATION DEEMED TO BE UNIVERSITY   (India)

Author keywords

Body mass index (BMI); Glycosylated haemoglobin (HbA1c); High sensitive C reactive protein (hsCRP); Hypoglycaemic drugs Insulin (HGDI); Hypoglycaemic drugs (HGD); Malondialdehyde (MDA)

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; MALONALDEHYDE; METFORMIN; SULFONYLUREA; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ASSAY; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; FERRIC REDUCING ABILITY OF PLASMA LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POSTPRANDIAL BLOOD SUGAR; PROSPECTIVE STUDY; RISK FACTOR;

EID: 84940655430     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/14218.6449     Document Type: Article

References (31)

1. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393-403.
2. Mazzola N. Review of current and emerging therapies in type 2 diabetes mellitus. Am J Manag care. 2012; 18: S17-S26.
3. Riddle MC, Rosenstock J, et al. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26: 3080‑86.
4. Nguyen DV, Lynn C, et al. Inflammation in the pathogenesis of microvascular complications in diabetes. Frontiers in Endocrinology. 2012; 3: Article170.
5. Ramakrishna V, Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2008; 45: 41-46.
6. Philip S, Abraham P, Kanakasabai G, Sethupathy S, Sheriff DS. Serum high sensitive C-reactive protein and anticardiolipin antibody level in CAD patients with and without type 2 diabetes mellitus. International Journal of Applied Biology and Pharmaceutical Technology. 2012; 3: 196-202.
7. Festa A, D' Agostino R, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102: 42-47.
8. Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis. Circulation. 2002; 105: 1135-43.
9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55: 1577-96.
10. Chris R. Triggle and Hong Ding. Cardiovascular impact of drugs used in the treatment of diabetes. Therapeutic Advances in Chronic Disease. 2014; 5(6): 245-68.
11. Hundal RS, Inzucchi SE. Metformin New understandings, New uses. Drugs. 2003; 63(18): 1879-94.
12. Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012; 55: 636-43.
13. Turner RC. The UK Prospective Diabetes Study A review. Diabetes care. 1998; (Suppl 3): C35-C38.
14. Khan R. Weight gain and insulin therapy. British Journal of Diabetes & Vascular Disease. 2004; 4: 264-67.
15. Solano MP, Goldberg RB. Lipid management in type 2 diabetes. Clinical Diabetes. 2006; 24: 27-32.
16. Henry RR. Preventing cardiovascular complications of type 2 diabetes: Focus on lipid management. Clinical Diabetes. 2001; 19: 113-20.
17. Toledo FGS, Sniderman AD, et al. Influence of hepatic steatosis (Fatty Liver) on severity and complication of dyslipidemia in type 2 diabetes. Diabetes Care. 2006; 29: 1845-50.
18. Kassem SA, Raz I. Are These Evidence That oral hypoglycaemic agents reducing cardiovascular morbidity or mortality? No. Diabetes Care. 2009; 32: S337-41.
19. Alam R, Khan S, et al. MDA and antioxidants status in type 2 diabetes mellitus. NJIRM. 2013; 4(6): 75-78.
20. Song F, Hu YY, et al. Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed Type 2 diabetes. Clinical Science. 2007; 112: 599-606.
21. Espinosa A, Garcia A, Hartel S, et al. NADPH and hydrogen peroxide mediate insulin-induced calcium increase in skeletal muscle cells. Journal of Biological Chemistry. 2009; 284: 2568-75.
22. Bembde AS. A study of plasma fibrinogen level in type-2 diabetes mellitus and its relation to glycaemic control. Indian J Hematol Blood Transfus. 2012; 28(2): 105‑08.
23. Desai KNP, Roopakala MS, et al. Evaluation of plasma fibrinogen levels in type 2 diabetes mellitus. Int J Diabetes Dev Ctries. 2012; 32(4): 209-13.
24. Pierpaola DF, Margaret GG, Haymond MW. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. J Clin Invest. 1991; 88: 833-40.
25. Mojahedi MJ, Bonakdaran S, et al. Elevated Serum C-reactive protein level and microalbuminuria in patients with type 2 diabetes mellitus. Iranian Journal of Kidney Diseases. 2009; 3: 12-16.
26. Pfutzner A, Standl E, Strotmann, et al. Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus. Clin Chem Lab Med. 2006; 44(5): 556-60.
27. Mita T, Watada H, et al. Association of high-sensitive C-reactive protein with early-stage carotid atherosclerosis in Japanese patients with early-stage type 2 diabetes mellitus. Endocrinal Journal. 2006; 53: 693-98.
28. Nishitani N, Sakakibara H. Association between body mass index and highsensitivity C-reactive protein in male Japanese. Asian Oceanian Association for the Study of Obesity. 2013; 7: e297-e300.
29. Hayashino Y, Mashitani T, et al. Elevated levels of hs-CRP are associated with high prevalence of depression in Japanese patients with type 2 diabetes: The Diabetes Distress and Care Registry at Tenri (DDCRT 6). Diabetes Care. 2014; 37: 2459-65.
30. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001; 286: 327-34.
31. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350: 1387-97.